Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix

Journal of Clinical Investigation

Volumn 100, Issue 4, 1997, Pages 847-854

  Mitsuhashi, Tomoko ^a   Li, Yong Ming ^a   Fishbane, Steven ^b   Vlassara, Helen ^a  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

AGE affinity column; Diabetic renal failure; Glycotoxin; Hemodialysis; Lysozyme

Indexed keywords

AMINOGUANIDINE; BOVINE SERUM ALBUMIN; CLUSTERIN; COMPLEMENT COMPONENT C3B; GLYCOSYLATED PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; LYSOZYME;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; DIABETES MELLITUS; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; SERUM; UREMIA;

EID: 1842294592     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119600     Document Type: Article

References (47)

1. Brownlee, M., A. Cerami, and H. Vlassara. 1988. Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318:1315-1321.
2. Koschinsky, T., C. He, T. Mitsuhashi, R. Bucala, C. Liu, C. Buenting, K. Heitmann, and H. Vlassara. 1997. Orally absorbed reactive glycation products (glycotoxin): an environmental risk factor in diabetic nephropathy. Proc. Natl. Acad. Sci. USA. 94:6474-6479.
3. Brownlee, M. 1994. Glycation and diabetic complications. Diabetes. 43: 836-841.
4. Vlassara, H., R. Bucala, and L. Striker. 1994. Pathogenetic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 70:138-151.
5. Mitsuhashi, T., H. Nakayama, T. Itoh, S. Kuwajima, S. Aoki, T. Atsumi, and T. Koike. 1993. Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. Diabetes. 42:826-832.
6. Makita, Z., H. Vlassara, A. Cerami, and R. Bucala. 1992. Immunochemical detection of advanced glycation end products in vivo. J. Biol. Chem. 267: 5133-5138.
7. Papanastasiou, P., L. Grass, H. Rodela, A. Patrikarea, D. Oreopoulos, and E.P. Diamandis. 1994. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis. Kidney Int. 46: 216-222.
8. Nakamura, Y., Y. Horii, T. Nishino, H. Shiiki, Y. Sakaguchi, T. Kagoshima, K. Dohi, Z. Makita, H. Vlassara, and R. Bucala. 1993. Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143:1649-1656.
9. Kume, S., M. Takeya, T. Mori, N. Araki, H. Suzuki, S. Horiuchi, T. Kodama, Y. Miyauchi, and K. Takahashi. 1995. Immunochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am. J. Pathol. 147:654-667.
10. Philips, D. 1966. The three-dimensional structure of an enzyme molecule. Sci. Am. 215:78-90.
11. Anderson, B., H.M. Baker, G.E. Norris, S.V. Rumball, and E.N. Baker. 1992. Apo-lactoferrin structure demonstrates ligand-induced conformational change in transferrins. Nature (Lond.). 344:784-787.
12. Reiter, B., and J.D. Oram. 1969. Bacterial inhibitors in milk and other biological fluids. Nature (Lond.). 216:643-658.
13. Tenovuo, J., M. Lumikari, and T. Soukka. 1991. Salivary lysozyme, lactoferrin and peroxidases: antibacterial effects on cariogenic bacteria and clinical applications in preventive dentistry. Proc. Finn. Dent. Soc. 87:197-208.
14. Li, Y.M., A.X. Tan, and H. Vlassara. 1995. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat. Med. 1:1057-1061.
15. Li, Y.M., T. Mitsuhashi, and H. Vlassara. 1995. Lysozyme enhances endocytosis of glycated proteins by macrophages. Diabetes. 44(Suppl. 1):72a.
16. Li, Y.M., T. Mitsuhashi, G. Baviello, and H. Vlassara. 1996. Opsonization of removal of serum AGEs by coupling to lysozyme. Diabetes. 45(Suppl. 2):239a.
17. Mitsuhashi, T., H. Vlassara, H.W. Founds, and Y.M. Li. 1997. Standardizing the immunological measurement for advanced glycation endproducts using normal human serum. J. Immunol. Methods. In press.
18. Lowry, O.H., N.J. Rosebrough, A.L. Farr, and R.J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
19. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoresis of proteins from polyacrylamide gels to nitrocellulose sheet: procedure and some applications. Proc. Natl. Acad. Sci. USA. 76:4350-4354.
20. Moos, M. 1992. Isolation of proteins for microsequence analysis. In Current Protocol in Immunology. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, editors. Greene Publishing Associates and John Wiley & Sons, New York. 8.7.1-8.7.12.
21. Matsudaira, P. 1987. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J. Biol. Chem. 262: 10035-10038.
22. Brownlee, M., H. Vlassara, A. Kooney, P. Ulrich, and A. Cerami. 1986. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science (Wash. DC). 232:1629-1632.
23. Vlassara, H., H. Fuh, T. Donnelly, and M. Cybulsky. 1995. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbit. Mol. Med. 1:447-456.
24. Vlassara, H., H. Fuh, Z. Makita, S. Krungkrai, A. Cerami, and R. Bucala. 1992. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc. Natl. Acad. Sci. USA. 89:12043-12047.
25. Skolnik, E.Y., Z. Yang, Z. Makita, S. Radoff, M. Kirstein, and H. Vlassara. 1991. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodeling and diabetic nephropathy. J. Exp. Med. 174:931-939.
26. Makita, Z., R. Bucala, E.J. Rayfield, E.A. Friedman, A.M. Kaufman, S.M. Korbet, R.H. Barth, J.A. Winston, H. Fuh, K. Manogue, A. Cerami, and H. Vlassara. 1994. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet. 343:1519-1522.
27. Fishbane, S., J. Maesaka, T. Mitsuhashi, G. Adam, and H. Vlassara. 1995. In-vitro clearance of advanced glycosylated endproducts (AGE) by conventional and high-flux hemodialysis (HD) membrane. J. Am. Soc. Nephrol. 6:488.
28. Fishbane, S., R. Bucala, T. Koschinsky, D. Giordano, H. Founds, and H. Vlassara. 1995. Significant reduction of plasma LDL-Apo B and glycated Apo B following chronic high-flux hemodialysis in diabetic uremic patients. J. Am. Soc. Nephrol. 6:487.
29. Makita, Z., S. Radoff, E.J. Rayfield, Z. Yang, E. Skolnik, V. Delaney, E.A. Friedman, A. Cerami, and H. Vlassara. 1991. Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J. Med. 325:836-842.
30. Bucala, R., Z. Makita, T. Koschinsky, A. Cerami, and H. Vlassara. 1993. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc. Natl. Acad. Sci. USA. 90:6434-6438.
31. Ahmed, M.U., S.R. Thorpe, and J.W. Banes. 1986. Identification of carboxymethyllysine as a degradation product of fructosyllysine in glycated protein. J. Biol. Chem. 261:4889-4894.
32. Sell, D.R., and V.M. Monnier. 1989. Structure elucidation of senescence crosslink from human extracellular matrix: implication of pentoses in the aging process. J. Biol. Chem. 264:21597-21602.
33. 2-microglobulin modified with advanced glycation endproducts is a major component of hemodialysis-associated amyloidosis. J. Clin. Invest. 92:1243-1252.
34. Li, Y.M., T. Mitsuhashi, J. Radvich, and H. Vlassara. 1996. A novel affinity dialyzer for the removal of advanced glycation endproducts (AGEs) from the serum of dialysis patient. J. Am. Soc. Nephrol. 7:1412.
35. Kennedy, D.M., A.W. Skillen, and C.H. Self. 1994. Glycation of monoclonal antibodies impairs their ability to bind antigen. Clin. Exp. Immunol. 98: 245-251.
36. Dolhofer, R., E.A. Siess, and O.H. Wieland. 1985. Nonenzymatic glycation of immunoglobulins leads to an impairment of immunoreactivity. Biol. Chem. Hoppe-Seyler. 366:361-366.
37. Hennessey, P.J., C.T. Black, and R.J. Andrassy. 1991. Nonenzymatic glycosylation of immunoglobulin G impairs complement fixation. J. Parenter. Enteral. Nutr. 15:60-64.
38. Buttyan, R., C.A. Olsson, J. Pintar, C. Chang, M. Brandyk, P.-Y. Ng, and I.S. Sawczuk. 1989. Induction of the TRPM 2 gene in cells undergoing programmed death. Mol. Cell. Biol. 9:3473-3481.
39. Collard, M.W., and M.D. Griswold. 1987. Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells. Biochemistry. 26: 3297-3303.
40. Choi, N.-H., T. Mazda, and M. Tomita. 1989. A serum protein SP-40,40 modulates the formation of membrane attack complex of complement on erythrocytes. Mol. Immunol. 26:835-840.
41. Danik, M., J.-G. Chabot, C. Mercier, A.-L. Benabid, C. Chauvin, R. Quirion, and M. Suh. 1991. Human gliomas and epileptic foci express high levels of mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc. Natl. Acad. Sci. USA. 88:8577-8581.
42. Palmer, D.J., and D.L. Christie. 1990. The primary structure of glycoprotein III from bovine adrenal medullary chromaffin granules. Sequence similarity with human serum protein-40,40 and rat Sertoli cell glycoprotein. J. Biol. Chem. 265:6617-6623.
43. De Silva, H.V., W.D. Stuart, C.R. Duvic, J.R. Wetterau, M.J. Ray, D.G. Ferguson, H.W. Albers, W.R. Smith, and J.A.K. Harmony. 1990. A 70-kDa apolipoprotein designated apoJ is a marker for subclasses of human plasma high density lipoproteins. J. Biol. Chem. 265:13240-13247.
44. James, R.W., A.-C. Hochstrasser, I. Borghini, B. Martin, D. Pometta, and D. Hochstrasser. 1991. Characterization of human high density lipoprotein-associated protein. NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated cytosis. Arterioscler. Thromb. 11:645-652.
45. Ghiso, J., E. Matsubara, A. Koudinov, N.-H. Choi-Miura, M. Tomita, T. Wisniewski, and B. Frangione. 1993. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of complement membrane-attack complex. Biochem. J. 293:27-30.
46. Zlokovic, B.V., C.L. Martel, J.B. Mackic, E. Matsubara, T. Wisniewski, J.G. McComb, B. Frangione, and J. Ghiso. 1994. Brain uptake of circulating apolipoprotein J and E complexed to Alzheimer's amyloid beta. Biochem. Biophys. Res. Commun. 205:1431-1437.
47. Kleso, G.J., W.D. Stuart, R.J. Richter, C.E. Furlong, T.C. Jordan-Starck, and J.A.K. Harmony. 1994. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 33:832-839.